A phase i study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL

Leukemia

Volumn 24, Issue 11, 2010, Pages 1972-1975

  Brown, J R ^a,b   Abramson, J ^b,c   Hochberg, E ^b,c   Mikler, E ^a   Dalton, V ^a   Werner, L ^a   Reynolds, H ^a   Thompson, C ^a   McDonough, S M ^a   Kuang, Y ^a   Ritz, J ^a,b   Neuberg, D ^a   Freedman, A S ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACICLOVIR; ALLOPURINOL; BILIRUBIN; CALCIUM PHOSPHATE; CREATININE; CYTOKINE; FLUDARABINE; IBUPROFEN; LACTATE DEHYDROGENASE; LENALIDOMIDE; METHYLPREDNISOLONE; OXYCODONE; RITUXIMAB; SULFAMETHOXAZOLE; TRIMETHOPRIM; URIC ACID;

ADULT; AGED; CANCER REGRESSION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOPENIA; DEEP VEIN THROMBOSIS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; INFLAMMATION; LETTER; MALE; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; T LYMPHOCYTE; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR FLARE;

EID: 78149466993     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.199     Document Type: Letter

References (8)

1. Chanan-Khan A, Miller KC, Musial L, Lawrence D, Padmanabhan S, Takeshita K et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006; 24: 5343-5349.
2. Ferrajoli A, Lee BN, Schlette EJ, O'Brien SM, Gao H, Wen S et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008; 111: 5291-5297.
3. Aue G, Njuguna N, Tian X, Soto S, Hughes T, Vire B et al. Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lympho-cytic leukemia. Haematologica 2009; 94: 1266-1273.
4. Andritsos LA, Johnson AJ, Lozanski G, Blum W, Kefauver C, Awan F et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 2008; 26: 2519-2525.
5. Moutouh-de Parseval LA, Weiss L, DeLap RJ, Knight RD, Zeldis JB. Tumor lysis syndrome/tumor flare reaction in lenalidomide- treated chronic lymphocytic leukemia. J Clin Oncol 2007; 25: 5047 (letter).
6. Lapalombella R, Andritsos L, Liu Q, May SE, Browning R, Pham LV et al. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase dependent pathway. Blood 2009; 115: 2619-2629.
7. Egle A, Steurer M, Melchardt T, Stoll M, Greil R. The REVLIRIT CLL5 AGMT Study - a phase I/II trial combining Fludarabine/Rituximab with escalating doses of lenalidomide followed by Rituximab/Lenalidomide in untreated CLL: results of a planned interim analysis. Blood 2009; 114: 3453 (abstract).
8. Ferrajoli A, Badoux XC, O'Brien S, Wierda WG, Faderl S, Estrov Z et al. Combination therapy with Lenalidomide and Rituximab in patients with relapsed chronic lymphocytic leukemia (CLL). Blood 2009; 114: 206 (abstract).